Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Thrombocytopenia heparins

The second type of heparin-induced thrombocytopenia is severe and may be associated with a platelet count below 100,000/mm and thrombosis. ° ° The platelet count generally begins to decline 5 to 10 days after the start of heparin therapy (sooner in patients previously treated with heparin). Thrombocytopenia and thrombosis may develop with low-dose heparin, heparin-coated catheters, or even heparin flushes. Historically, the reaction was thought to be mediated by the formation of antibodies to the platelet-heparin complex. However, evidence suggests a complex interaction between heparin, platelet factor 4 (PF4), platelet membrane Fc receptors, and possibly heparin-like molecules on the surface of endothehal cells (Fig. 102-6). Circulating heparin reacts with PF4 to produce a... [Pg.1885]

The major side effect is bleeding, as is the case with abciximab. The frequency of major bleeding in trials was about 10%, compared with about 9% in a placebo group, which included heparin. Thrombocytopenia has been seen in 0.5 to 1% of patients. [Pg.235]

Arepally GM, Ortel TL (2006) Clinical practice. Heparin-induced thrombocytopenia. N Engl JMed 355 809-817... [Pg.112]

The LMWHs are contraindicated in patients witii a hypersensitivity to the drug, heparin, or pork products and inpatients with active bleeding or thrombocytopenia... [Pg.425]

A complete blood count, platelets, and stools for occult blood may be ordered periodically throughout therapy. Thrombocytopenia may occur during heparin administration. A mild, transient thrombocytopenia may occur 2 to 3 days after heparin therapy is begun. This early development of thrombocytopenia tends to resolve itself despite continued tiierapy. The nurse reports a platelet count of less than 100,000 mm3 immediately because die primary care provider may choose to discontinue die heparin therapy. [Pg.426]

Figure 24.4 The decision-analytic model shows the three strategies that were examined by Arnold and researchers [22] to evaluate the financial implications of the direct thrombin inhibitor argatroban for early treatment (<48 hours after thrombocytopenia onset), compared with delayed treatment, of heparin-induced thrombocytopenia (HIT) with or without thrombosis. Figure 24.4 The decision-analytic model shows the three strategies that were examined by Arnold and researchers [22] to evaluate the financial implications of the direct thrombin inhibitor argatroban for early treatment (<48 hours after thrombocytopenia onset), compared with delayed treatment, of heparin-induced thrombocytopenia (HIT) with or without thrombosis.
Arnold R, Kim R, Zhou Y, Tang B. Budgetary impact of heparin-induced thrombocytopenia with thrombosis and treatment with the direct thrombin inhibitor Argatroban (P401E). ASHP 39th Midyear Clinical Meeting. Orlando, FL, 2004. [Pg.588]

Arnold R, Kim R, Tang B. The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia the effect of early versus delayed treatment. Cardiol Rev 2005 14 7-13. [Pg.588]

Hemorrhage is the main complication that can arise from heparin therapy. Other side effects include Heparin-Induced Thrombocytopenia Syndrome (HITS), local irritation, hypersensitivity reactions and with long-term use, alopecia, hypoaldoster-onism, and osteoporosis. [Pg.137]

Avoid warfarin monotherapy during the acute phase of heparin-induced thrombocytopenia (HIT)... [Pg.121]

Unfractionated heparin Bleeding, heparin-induced thrombocytopenia Clinical signs of bleeding3 baseline CBC and platelet count aPTT every 6 hours until target then every 24 hours daily CBC platelet count every 2 days (minimum, preferably every day)... [Pg.103]

DVT, deep vein thrombosis HIT, heparin-induced thrombocytopenia PAI-I, plasminogen activator inhibitor PE, pulmonary embolism SERM, selective estrogen receptor modulator VTE, venous thromboembolism. [Pg.135]

Heparin-induced thrombocytopenia (HIT) is a very serious adverse effect associated with UFH use. Platelet counts should be monitored every 2 to 3 days dining the course of UFH therapy.5 HIT should be suspected if the platelet count drops by more than 50% from baseline or to below 120,000. In patients with contraindications to anticoagulation therapy, UFH should not be administered (Table 7-7). [Pg.146]

HIT, heparin-induced thrombocytopenia INR, International Normalized Ratio LMWHs, low-molecular-weight heparins PT, prothrombin time UFH, unfractionated heparin. [Pg.146]

If the patient is treated with UFH or LMWH and platelet count has dropped by more than 50% from baseline or is less than 120x1 OVjil, evaluate the patient for heparin-induced thrombocytopenia (HIT). [Pg.159]

HIT heparin-induced thrombocytopenia t-PA tissue plasminogen activator... [Pg.159]

Type II IgG Hemolytic anemia, thrombocytopenia Quinidine, methyldopa, penicillins, heparin... [Pg.822]

Deep vein thrombosis prophylaxis is recommended for septic patients. Low-dose unfractionated heparin or low-molecular-weight heparin may be utilized. Graduated compression stockings or an intermittent compression device is recommended for patients with a contraindication to heparin products (thrombocytopenia, severe coagulopathy, active bleeding, or recent intracerebral hemorrhage).24... [Pg.1195]

The benefit and necessity of adding heparin to PN are unclear. There are also concerns about the stability/compatibility of intravenous lipid emulsions with heparin added at concentrations above 1 unit/mL. Heparin should be omitted in patients with active bleeding, thrombocytopenia, heparin-induced thrombocytopenia (HIT), or heparin allergy. [Pg.1499]

Heparin-induced thrombocytopenia A clinical syndrome of IgG antibody production against the heparin-platelet factor 4 complex occurring in approximately 1% to 5% of patients exposed to either heparin or low-molecular-weight heparin. Heparin-induced thrombocytopenia results in excess production of thrombin, platelet aggregation, and thrombocytopenia (due to platelet clumping), often leading to venous and arterial thrombosis, amputation of extremities, and death. [Pg.1567]

Refludan Lepirudin Hoechst Marion Roussel Heparin-induced thrombocytopenia type II... [Pg.695]


See other pages where Thrombocytopenia heparins is mentioned: [Pg.1885]    [Pg.35]    [Pg.963]    [Pg.821]    [Pg.1885]    [Pg.35]    [Pg.963]    [Pg.821]    [Pg.111]    [Pg.111]    [Pg.111]    [Pg.112]    [Pg.1200]    [Pg.425]    [Pg.576]    [Pg.78]    [Pg.166]    [Pg.48]    [Pg.121]    [Pg.220]    [Pg.98]    [Pg.100]    [Pg.145]    [Pg.169]    [Pg.1509]   
See also in sourсe #XX -- [ Pg.30 , Pg.32 , Pg.404 , Pg.626 ]




SEARCH



Argatroban heparin-induced thrombocytopenia

Heparin induced thrombocytopenia

Heparin-induced thrombocytopenia alternative anticoagulants

Heparin-induced thrombocytopenia syndrome

Heparin-induced thrombocytopenia with thrombosis

Lepirudin heparin-induced thrombocytopenia

Thrombocytopenia

Thrombocytopenia heparin-associated

Thrombocytopenia with unfractionated heparin

Venous thromboembolism with heparin-induced thrombocytopenia

© 2024 chempedia.info